Openbookopenbook
Equity
Fagron NV(0HNZ)
EUR --+0.00%
Reward56Moderate
Risk13Low
📊50%Data
2.7% dividend yield
0HNZ
+0.0 · +0.00%
EUR · LSE
Fagron NV |
Defensive Anchor
Market Cap:1.16Bn
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
13
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0HNZ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Fagron NV?

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide.

0HNZ · Verdict

Solid reward · low risk

0HNZ scores well on cash flow and volatility with no major weaknesses flagged in the model.

Based on 75% data coverage

0HNZ · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow95/100

    Top decile vs peers

  • Volatility95/100

    Top decile vs peers

  • Balance sheet84/100

    Current ratio 1.86

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Fagron NV?

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company is listed on the LSE in UK, with a market capitalisation of 1.16B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap1.16B
P/E RatioN/A
Dividend Yield2.66%
52 Week High24.45
52 Week Low19
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees4,193
IndustryN/A
ExchangeLSE
Beta0.332
CurrencyEUR
Websitewww.fagron.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.